Tick-borne antigen panel
February 2019—ChromaCode announced the commercial launch of its first multiplex test using the company’s proprietary high-definition polymerase chain reaction technology.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
FDA approves larotrectinib
February 2019—The FDA granted accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.
FDA clears Accula RSV molecular POC test
February 2019—Mesa Biotech has received 510(k) clearance and CLIA waiver from the FDA for its Accula RSV test, cleared for diagnosing children and adults.
Keytruda for HCC gets accelerated approval
February 2019—The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for patients with hepatocellular carcinoma who have been previously treated with sorafenib.
Inova Dx launches calprotectin extraction device
February 2019—Inova Diagnostics announced FDA clearance of its Fecal Extraction Device for use in conjunction with Quanta Flash Calprotectin, which aids in the diagnosis of inflammatory bowel disease and helps differentiate IBD from irritable bowel syndrome.
Dragonfly, Celgene expand collaboration
February 2019—Dragonfly Therapeutics has entered into a new agreement with Celgene to discover, develop, and commercialize immunotherapies for patients with solid and hematological cancers.
Pembrolizumab approved for Merkel cell carcinoma
February 2019—The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
LGC acquires SeraCare Life Sciences
February 2019—London-based LGC announced the acquisition of SeraCare Life Sciences. SeraCare provides quality control materials for infectious disease testing through its Accurun reagents and next-generation sequencing reference materials through its Seraseq products for oncology, noninvasive prenatal testing, and inherited disease testing.
ArcherDx cDx assay gets breakthrough designation
February 2019—ArcherDx announced that the FDA granted a breakthrough device designation for its companion diagnostic assay application.
NxGen MDx offers hereditary cancer panel
February 2019—NxGen MDx introduced its NxGen MDx Hereditary Cancer Panel, which tests for variants in 32 genes known to cause certain forms of hereditary cancer.